Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Etoposide 3Carboplatin 3atezolizumab 2tislelizumab 1pembrolizumab 1irinotecan sucrosofate 1apatinib 1Radiotherapy 1Platinum 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Cancer Extensive Stage × apatinib × Clear all
NCT06429696 2025-05-28

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Nanfang Hospital, Southern Medical University

Phase 2 Recruiting
40 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡